{
  "phase": "Data Processing & Merging",
  "timestamp": "2025-11-18 21:35:14",
  "dataset_summary": {
    "total_matched_medicines": 24772,
    "total_unmatched_248k": 224240,
    "total_unmatched_11k": 4756,
    "total_unique_medicines": 253768
  },
  "coverage": {
    "248k_coverage_percent": 9.98,
    "11k_coverage_percent": 209.49,
    "total_medicines_in_both_datasets": 24772
  },
  "data_quality": {
    "merged_completeness_percent": 50.14,
    "key_features_availability": {
      "medicine_names": "100%",
      "therapeutic_class": "100%",
      "composition": "100%",
      "manufacturer": "100%",
      "primary_use": "100%",
      "primary_side_effect": "100%",
      "alternatives": "91.8%"
    },
    "side_effects_coverage": "16.0%",
    "uses_coverage": "41.2%"
  },
  "recommendations": [
    "\u2713 Use merged dataset (24,772 records) for Phase 2 ML training",
    "\u2713 Merged data has 100% availability of critical fields",
    "\u2713 Side effects: Use available sideeffect0-2 for primary effects",
    "\u2713 Uses: Use available use0-2 for symptom mapping",
    "\u2713 Unmatched medicines can be used as additional feature sources",
    "\u2713 Ready to proceed to Phase 2: Feature Engineering & ML Training"
  ]
}